Who is sponsoring NCT04320238?

NCT04320238 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04320238?

Interventions in NCT04320238: recombinant human interferon Alpha-1b, thymosin alpha 1.

What condition does NCT04320238 study?

NCT04320238 studies 2019 Novel Coronavirus Infection.

Is NCT04320238 still recruiting?

NCT04320238 is currently status unknown. Last updated 30 March 2020.

Last reviewed 2020-03-30 · How we verify

NCT04320238

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Clinic Trial of Recombinant Human Interferon Alpha Nasal Drops to Prevent Coronavirus Disease 2019 in Medical Staff in Epidemic Area

Status unknown Phase 3 Last updated 30 March 2020

What this trial tests

Phase 3 trial testing recombinant human interferon Alpha-1b in 2019 Novel Coronavirus Infection in 2,944 participants. Status unknown.

Timeline

21 January 2020

Primary endpoint
1 May 2020

1 June 2020

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	2,944
Start date	21 January 2020
Primary completion	1 May 2020
Estimated completion	1 June 2020
Sites	1 location across China

Drugs / interventions tested

recombinant human interferon Alpha-1b — full drug profile →
thymosin alpha 1 — full drug profile →

Conditions studied

2019 Novel Coronavirus Infection — all drugs for 2019 Novel Coronavirus Infection →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 65, any sex, with 2019 Novel Coronavirus Infection. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

new-onset COVID-19
Time frame: From date of randomization until the diagnosis of COVID-19, assessed up to 6 weeks.
new-onset coronavirus disease-2019

Sponsor's own description

The investigators plan to carry out an experimental study on the preventive effect of recombinant human interferon alpha nasal drops on the infection of 2019 new coronavirus in medical staff.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic.
Driggin E, Madhavan MV, Bikdeli B, Chuich T, et al · · 2020 · cited 1272× · PMID 32201335 · DOI 10.1016/j.jacc.2020.03.031
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.
Jamilloux Y, Henry T, Belot A, Viel S, et al · · 2020 · cited 486× · PMID 32376392 · DOI 10.1016/j.autrev.2020.102567
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
The signal pathways and treatment of cytokine storm in COVID-19.
Yang L, Xie X, Tu Z, Fu J, et al · · 2021 · cited 429× · PMID 34234112 · DOI 10.1038/s41392-021-00679-0
Dysregulation of type I interferon responses in COVID-19.
Acharya D, Liu G, Gack MU. · · 2020 · cited 388× · PMID 32457522 · DOI 10.1038/s41577-020-0346-x
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7
Viral Respiratory Pathogens and Lung Injury.
Clementi N, Ghosh S, De Santis M, Castelli M, et al · · 2021 · cited 127× · PMID 33789928 · DOI 10.1128/cmr.00103-20
COVID 19: a clue from innate immunity.
Birra D, Benucci M, Landolfi L, Merchionda A, et al · · 2020 · cited 119× · PMID 32524333 · DOI 10.1007/s12026-020-09137-5

Verify or expand the search:

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04320238 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 30 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320238.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing